Wikipedia -WSS

Wikipedia

author：comprehensive 2025-08-23 04:59:06 - browse：2

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： 23andMe had bad news about my health. I wish a person had delivered it
Next article： Radiation, mainstay of cancer treatment, begins a fade

knowledge

WSS

How AI can help patients find reliable information about doctors

Unicorn down: Following layoffs, Biofourmis CEO quietly departs

Roche drug slashes death risk in early

Radiation, mainstay of cancer treatment, begins a fade

CDC advisory panel says seniors 'may' get RSV vaccine

STAT Summit: Ending the crisis of Black deaths in the U.S.

knowledge

Wikipedia

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Dobbs anniversary: the lost opportunity of abortion as health care

Complete sequence of Y chromosome published for first time

After affirmative action ruling, medical educators look to 'holistic review'

AstraZeneca challenges Medicare drug negotiation program

Affirmative action in medical school literally saved lives

How AI can help patients find reliable information about doctors

Medicare details structure of new drug price negotiation program

STAT Summit: Ending the crisis of Black deaths in the U.S.

Continuity nursing helped my family in our darkest PICU moments

How to make Best Hospitals ratings actually useful for patients

leisure time

How AI can help patients find reliable information about doctors

AstraZeneca challenges Medicare drug negotiation program

Winners, losers from Medicare’s list of drugs subject to price talks

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Health tech investors get more selective as pandemic boom fades

Is there really a nursing shortage in the U.S.?

knowledge

explore

knowledge

Wikipedia